Compass Therapeutics says a treatment evaluating its cancer treatment didn’t meet the secondary endpoint for an unexpected ...
Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company, is seeking to raise as much as $212 million in a US ...
If you bought XBI a year ago and held it, you are up roughly 65%. If you bought Direxion Daily S&P Biotech Bull 3X Shares ...
Add Yahoo as a preferred source to see more of our stories on Google. Lululemon launched its first product using plant-based nylon in April 2023 Biotechnology is the exploitation of biological ...
Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for about $739 million in cash, the companies said on Monday. The deal adds more than 120 treatments, including ...
Vir Biotechnology has dosed the first patient in one of three expansion cohorts in its ongoing Phase I clinical trial of ...
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer – Updated Phase 1 ...
AV Laboratories is redefining the future of skincare by translating decades of advanced biotechnology research into clinically driven formulations designed for everyday use. Rooted in expertise ...
Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this ...
Debut Biotech, a company innovating new molecules, is partnering with Image Skincare to launch a new beauty product, CNBC has learned. The San Diego-based company uses biotechnology and artificial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results